Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 18
Summary
- Conditions
- Stage IIB Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Stage I Ovarian Cancer
- Stage IA Ovarian Cancer
- Stage IIIC Ovarian Cancer
- Stage IB Ovarian Cancer
- Stage IC Ovarian Cancer
- Stage II Ovarian Cancer
- Stage IIIB Ovarian Cancer
- Stage IV Ovarian Cancer
- Stage IIA Ovarian Cancer
- Stage IIC Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IIIA Ovarian Cancer
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
PRIMARY OBJECTIVES: I. To determine the feasibility of performing intravital microscopy on accessible human ovarian, primary peritoneal and fallopian tube cancers during their standard course of treatment (i.e., surgical debulking). SECONDARY OBJECTIVES: I. To determine the blood flow velocity of th...
PRIMARY OBJECTIVES: I. To determine the feasibility of performing intravital microscopy on accessible human ovarian, primary peritoneal and fallopian tube cancers during their standard course of treatment (i.e., surgical debulking). SECONDARY OBJECTIVES: I. To determine the blood flow velocity of the tumor vessels and tissue penetration of fluorescein as a marker of tumor vessel permeability. OUTLINE: Patients receive fluorescein sodium injection intravenously (IV). Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery. After completion of study, patients are followed up for 30 days, at 1-3 weeks, and then up to 2 years.
Tracking Information
- NCT #
- NCT03297489
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Emese Zsiros, MD Roswell Park Cancer Institute
Get Well Soon